Shiga Toxin, Stx2e, Influences the Activity of Porcine Lymphocytes In Vitro
Daniel Sperling, Hana Stepanova, Han Smits, Anne-Kathrin Diesing and Martin Faldyna
Shiga-Toxin-Stx2e-In (1.61 MB)DownloadThe first, innovative and leading piglet vaccine which induces neutralising antibodies against Shigatoxin, the cause of Edema Disease.
Available in :
The introduction of Ecoporc SHIGA in Europe in 2013 has been a revolution and an innovation in approaching Edema Disease (ED). Latest results from a prevalence study in Germany show a Shigatoxin producing E.coli (EDEC) farm prevalence of 24%. Vaccination rates in some EU countries between 10% and 30% of the piglet population support these findings. The geographical extension is progressing with licenses in Canada and the Ukraine, soon in Japan and in all the swine Asian and Latin American countries. Ecoporc Shiga has a huge potential in all the swine countries!
Increase of productivity
Economically sustainable
AMR reduction and environmental requirements can be met
Daniel Sperling, Hana Stepanova, Han Smits, Anne-Kathrin Diesing and Martin Faldyna
Shiga-Toxin-Stx2e-In (1.61 MB)DownloadSander Van hoorde, Bert Devriendt, Daniel Sperling, H. Xiaohua, Eric Cox
Influence-of-host-fa (1.38 MB)DownloadDaniel Sperling, Naomi Isaka, Hamadi Karembe, Jonas Vanhara, Josef Vinduska, Nicol Strakova, Alzbeta Kalova, Ivana Kolackova, Renata Karpiskova
Effect-of-the-vaccin (319.87 KB)DownloadSander Van hoorde, Bert Devriendt, Daniel Sperling, Eric Cox
Comparative-analysis (1.82 MB)DownloadFrom one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.